Dyslipidemia management update

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Hypercholesterolemia is a known risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Therapeutic strategies traditionally focus on reducing low-density lipoprotein-cholesterol (LDL-C) and increasing high-density lipoprotein-cholesterol (HDL-C).
• Conventional cholesterol-lowering medications include statins, ezetimibe, and bile-acid sequestrants.

Purpose of the Study:

• To review recent advancements in cholesterol-lowering therapies.
• To evaluate the efficacy of novel drug classes for hypercholesterolemia.
• To explore potential new therapeutic targets for cardiovascular risk reduction.

Main Methods:

• Review of clinical trials and recent approvals of novel cholesterol-lowering agents.
• Analysis of the impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies on LDL-C levels.
• Evaluation of apolipoprotein B-100 (Apo B-100) antisense and microsomal triglyceride transfer protein (MTP) inhibitors.
• Assessment of outcomes from trials investigating HDL-raising drugs and reverse cholesterol transport.

Main Results:

• PCSK9 antibodies, when added to statin therapy, can reduce LDL-C by up to 60%.
• ApoB antisense and MTP inhibitors are approved for homozygous familial hypercholesterolemia.
• Many HDL-raising drug trials have yielded unpromising results.
• Enhancing reverse cholesterol transport shows potential as a novel therapeutic strategy.

Conclusions:

• Novel therapies like PCSK9 antibodies offer significant LDL-C reduction for inadequately controlled hypercholesterolemia.
• Current HDL-targeting drugs have limited success, suggesting a shift towards targeting reverse cholesterol transport.
• Future research may focus on modulating reverse cholesterol transport to mitigate cardiovascular risk.